Bone health monitoring clinical laboratory and image evaluation in Duchenne muscular dystrophy with steroid treatment

2016 ◽  
Vol 26 ◽  
pp. S121
Author(s):  
R. Escobar ◽  
A. Ocon ◽  
S. Renan ◽  
E. Martinez ◽  
L. Lopéz ◽  
...  
2019 ◽  
Vol 29 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Shuko Joseph ◽  
Cunyi Wang ◽  
Marina Di Marco ◽  
Iain Horrocks ◽  
Ishaq Abu-Arafeh ◽  
...  

2017 ◽  
Author(s):  
Nicola Crabtree ◽  
Wolfgang Hogler ◽  
Helen Roper ◽  
Nicholas Shaw

2019 ◽  
Author(s):  
Verene Chua ◽  
Craig Munns ◽  
Andrew Biggin

2005 ◽  
Vol 15 (1) ◽  
pp. 80-85 ◽  
Author(s):  
W.D. Biggar ◽  
L.K. Bachrach ◽  
R.C. Henderson ◽  
H. Kalkwarf ◽  
H. Plotkin ◽  
...  

2016 ◽  
Vol 26 ◽  
pp. S121
Author(s):  
H. Peay ◽  
A. Martin ◽  
P. Ruddle ◽  
J. Lavigne ◽  
K. Kinnett ◽  
...  

2017 ◽  
Vol 53 (12) ◽  
pp. 1247-1248 ◽  
Author(s):  
Angelina Lim ◽  
Margaret Zacharin ◽  
Janne Pitkin ◽  
Katy de Valle ◽  
Monique M Ryan ◽  
...  

2019 ◽  
Vol 29 ◽  
pp. S176
Author(s):  
A. Pietrusz ◽  
M. Desikan ◽  
F. Trucco ◽  
A. Manzur ◽  
F. Muntoni ◽  
...  

1977 ◽  
Vol 23 (12) ◽  
pp. 2341-2343 ◽  
Author(s):  
H L Verrill ◽  
N A Pickard ◽  
H D Gruemer

Abstract Currently, the most useful clinical laboratory aid in establishing the carrier state of Duchenne muscular dystrophy is to determine creatine kinase (EC 2.7.3.2) activity in the plasma. The considerable overlap between plasma creatine kinase activities of controls and of carriers at the childbearing age contributes appreciable difficulty to genetic counseling of potential carriers. The consistent failure of lymphocyte cap formation in Duchenne muscular dystrophy patients and carriers in this study suggests a valuable tool for the confirmation of the carrier state.


2016 ◽  
Vol 26 (11) ◽  
pp. 760-767 ◽  
Author(s):  
Cuixia Tian ◽  
Brenda L. Wong ◽  
Lindsey Hornung ◽  
Jane C. Khoury ◽  
Lauren Miller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document